UB-311

UB-311

UB-311 is a novel immunotherapeutic for the treatment of Alzheimer’s Disease. The UBI vaccine employs the UBITh helper T cell technology and a particular site-specific epitope to target the amyloid-beta peptide.

UB-311 has successfully completed Phase I, demonstrating safety and tolerability, and is currently in Phase II trials. Preliminary data showed efficacy as measured in improvement or stabilization in all three cognitive tests conducted in the target sub-population.